Strata Skin Sciences, INC 8-K filings

Strata Skin Sciences, Inc. announced its voluntary delisting from The Nasdaq Capital Market due to failure to meet minimum stockholders' equity requirements and an inability to secure sufficient funding without significant dilution.

Strata Skin Sciences, Inc. announced a significant market expansion opportunity with new CPT codes effective January 2027, alongside positive operational cash flow and a favorable injunction in the LaserOptek lawsuit.

STRATA SKIN SCIENCES, INC. stockholders approved the election of five directors, an increase in shares for the incentive plan, and the ratification of its independent auditor at the annual meeting.

STRATA Skin Sciences reported a 21% revenue decline in Q3 2025 to $6.9 million, alongside positive EBITDA and significant progress on CPT code expansion for its XTRAC laser.

Strata Skin Sciences, Inc. filed a prospectus supplement for its at-the-market equity distribution agreement, enabling the potential sale of up to $11.0 million in common stock.

Strata Skin Sciences, Inc. received an extension from Nasdaq until February 16, 2026, to regain compliance with the minimum stockholders' equity requirement.

STRATA Skin Sciences announced the successful closing of a registered direct offering, raising approximately $2.42 million for working capital and general corporate purposes.

Strata Skin Sciences, Inc. announced the pricing of a registered direct offering of 1,097,547 common shares at $2.204 each, expecting to raise approximately $2.42 million for working capital.

Strata Skin Sciences, Inc. received a notice from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement for continued listing.

STRATA Skin Sciences, Inc. highlights significant market expansion opportunities and strategic initiatives, including new CPT codes and a lawsuit, in its latest investor presentation.

STRATA Skin Sciences reported a 9% decline in second-quarter revenue to $7.7 million, alongside an increased net loss, while emphasizing strategic growth through expanded reimbursement codes for its XTRAC laser treatment.

STRATA Skin Sciences is working with CMS to accelerate reimbursement for its XTRAC laser, expanding its addressable market to over 30 million patients, while also advancing litigation against LaserOptek.

STRATA Skin Sciences announces the American Medical Association (AMA) has expanded reimbursement eligibility for excimer laser treatments to include multiple inflammatory and auto-immune skin conditions.

STRATA Skin Sciences announces a 1% revenue increase and significant gross margin expansion in the first quarter of 2025, alongside a corporate update.

Strata Skin Sciences replaces Marcum LLP with CBIZ CPAs P.C. as its independent registered public accounting firm, effective April 23, 2025.

STRATA Skin Sciences announces improved Q4 2024 financial results with revenue up 10% and progress in its turnaround strategy focused on cost efficiency and revenue per device.

STRATA Skin Sciences highlights a new clinical study from Japan demonstrating the superiority of narrow band excimer laser over non-narrow band UVB-source like excimer light for treating dermatologic conditions.

Strata Skin Sciences released an investor presentation detailing its business model, financial performance, and growth strategies, including a focus on recurring revenue and direct-to-consumer marketing.

STRATA Skin Sciences reported a slight year-over-year revenue decrease but achieved its first operating profit since 2018 in the third quarter of 2024, driven by improved gross margins and reduced operating expenses.

Strata Skin Sciences has obtained a court order against LaserOptek and its partners, restricting their marketing of Pallas lasers regarding reimbursement codes and false claims.

Strata Skin Sciences successfully held its annual meeting, electing five directors and ratifying Marcum, LLP as its independent auditor for the fiscal year ending December 31, 2024.

Strata Skin Sciences has filed a lawsuit against LaserOptek and its distributors alleging unfair competition related to the marketing and sales of competitive laser devices.

STRATA Skin Sciences announced a 2% year-over-year revenue increase for Q2 2024, alongside a reduction in operating expenses and a strategic realignment of its device base.

Strata Skin Sciences has successfully completed a $2.1 million registered direct offering of common stock, with participation from insiders and existing shareholders.

A clinical study published in the Journal of Cosmetic and Laser Therapy shows that Strata Skin Sciences' TheraClearX Acne Therapy System effectively reduces acne lesions and improves skin texture.

STRATA Skin Sciences reported preliminary second quarter 2024 revenue between $8.0 million and $8.4 million, with a decrease in XTRAC device installations and an increase in TheraClearX device installations.

STRATA Skin Sciences has received notification from Nasdaq that it has regained compliance with listing requirements and will continue to trade on the exchange.

Strata Skin Sciences has announced a 1-for-10 reverse stock split, effective June 6, 2024, to increase the per-share price of its common stock.

STRATA Skin Sciences reported a decrease in revenue for the first quarter of 2024, but showed signs of improvement in recurring billings and reduced operating expenses.

Strata Skin Sciences will implement a 1-for-10 reverse stock split effective June 6, 2024, to comply with Nasdaq's minimum bid price rule.